Clinical Trial

A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 17, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-23.
Trial Details
NCT Number NCT06952426
Lead Sponsor Novartis Pharmaceuticals
Conditions Immunoglobulin A Nephropathy
Enrollment 300 participants
Start Date 2025-03-04
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-17